Outcome in moderate haemophilia
- PMID: 23245711
- PMCID: PMC3934251
- DOI: 10.2450/2012.0091-12
Outcome in moderate haemophilia
Abstract
Background: Moderate haemophilia is the rarest form of haemophilia. This study aims to assess short- and long-term outcome, including its association with treatment, in patients with moderate haemophilia.
Material and methods: Seventy-five patients with moderate haemophilia (1-5% factor VIII/ factor IX activity), without a history of inhibitors, treated at the van Creveldkliniek, Utrecht (NL) were included in the study. Life-long data on bleeding and treatment were collected. Joints were evaluated using the Haemophilia Joint Health Score. Adults completed questionnaires on activity (HAL) and quality of life (SF-36, EQ5D).
Results: The median age of the patients was 37 years (IQR 23-52 years) and haemophilia A was diagnosed in 89%. Bleeding frequency was low: the median annual bleeding rate was 2.0 bleeds/ year (IQR 0.8-3.7 bleeds/year), including a median of 0 joint bleeds/year (IQR 0.8-3.7 bleeds/year). Joint function was good: 82% scored<10 out of 126 points of the Haemophilia Joint Health Score (HJHS). Nevertheless, 29% of patients with moderate haemophilia had a history of prophylaxis, because of a high bleeding frequency. Median age at first joint bleed was 4.8 years (IQR 3.5-8.5). Use of prophylaxis was more associated with age at first joint bleed (P<0.01) than with baseline factor activity (P=0.12). Most patients (52%) who suffered their first joint bleed before the age of 5 years required prophylaxis later in life.
Discussion: The majority of patients with moderate haemophilia have few bleeds and complications; however, a considerable subset of patients with a more severe bleeding pattern need prophylactic treatment. These latter patients may be identified by the onset of joint bleeding before the age of 5 years.
Figures



Comment in
-
Outcome in moderate haemophilia: back to the past? Remarks on haemophilia A classification and treatment.Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s311-2. doi: 10.2450/2013.0295-12. Epub 2013 Apr 18. Blood Transfus. 2014. PMID: 23736915 Free PMC article. No abstract available.
Similar articles
-
Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).Thromb Res. 2017 Mar;151:17-22. doi: 10.1016/j.thromres.2016.12.023. Epub 2016 Dec 28. Thromb Res. 2017. PMID: 28088606
-
[Prevention of joint damage in hemophilic children with early prophylaxis].Orthopade. 1999 Apr;28(4):341-6. doi: 10.1007/PL00003616. Orthopade. 1999. PMID: 10335528 Clinical Trial. German.
-
Turning severe into moderate haemophilia by prophylaxis: are we reaching our goal?Blood Transfus. 2013 Jul;11(3):364-9. doi: 10.2450/2012.0092-12. Epub 2012 Nov 6. Blood Transfus. 2013. PMID: 23149144 Free PMC article. Clinical Trial.
-
The treatment of haemophilia, including prophylaxis, constant infusion and DDAVP.Baillieres Clin Haematol. 1996 Jun;9(2):259-71. doi: 10.1016/s0950-3536(96)80062-x. Baillieres Clin Haematol. 1996. PMID: 8800504 Review.
-
Primary prophylaxis in children with haemophilia.Blood Transfus. 2008 Sep;6 Suppl 2(Suppl 2):s4-11. doi: 10.2450/2008.0030-08. Blood Transfus. 2008. PMID: 19105503 Free PMC article. Review.
Cited by
-
Treatment adherence in hemophilia.Patient Prefer Adherence. 2017 Sep 27;11:1677-1686. doi: 10.2147/PPA.S139851. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 29033555 Free PMC article. Review.
-
Comparison of Total Joint Replacement Rate Between Patients With Hemophilia A and Patients With Hemophilia B: A Population-Based and Retrospective Cohort Study.Clin Appl Thromb Hemost. 2018 Dec;24(9_suppl):163S-170S. doi: 10.1177/1076029618794294. Epub 2018 Sep 13. Clin Appl Thromb Hemost. 2018. PMID: 30213203 Free PMC article. Clinical Trial.
-
Long-term joint outcomes in adolescents with moderate or severe haemophilia A.Haemophilia. 2022 Nov;28(6):1054-1061. doi: 10.1111/hae.14636. Epub 2022 Aug 4. Haemophilia. 2022. PMID: 35925557 Free PMC article.
-
Asymptomatic Joint Bleeding and Joint Health in Hemophilia: A Review of Variables, Methods, and Biomarkers.J Blood Med. 2021 Apr 1;12:209-220. doi: 10.2147/JBM.S304597. eCollection 2021. J Blood Med. 2021. PMID: 33833602 Free PMC article. Review.
-
Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.Haemophilia. 2023 Jan;29(1):33-44. doi: 10.1111/hae.14676. Epub 2022 Oct 12. Haemophilia. 2023. PMID: 36224704 Free PMC article. Review.
References
-
- Report on the Global Survey. World federation of Haemophilia; 2008. [Accessed on: 27/01/2011]. Available at: www1.wfh.org/publications/files/pdf-1429.pdf.
-
- Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand. 1965;77(Suppl):3–132. - PubMed
-
- Plug I, van der Bom JG, Peters M, et al. Thirty years of hemophilia treatment in the Netherlands, 1972–2001. Blood. 2004;104:3494–500. - PubMed
-
- den Uijl IEM, Fischer K, van der Bom JG, et al. Clinical outcome of moderate haemophilia compared with severe and mild haemophilia. Haemophilia. 2009;15:83–90. - PubMed
-
- Lindvall K, Colstrup L, Wollter IM, et al. Compliance with treatment and understanding of own disease in patients with severe and moderate haemophilia. Haemophilia. 2006;12:47–51. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical